RS59139B1 - Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze - Google Patents

Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze

Info

Publication number
RS59139B1
RS59139B1 RS20190993A RSP20190993A RS59139B1 RS 59139 B1 RS59139 B1 RS 59139B1 RS 20190993 A RS20190993 A RS 20190993A RS P20190993 A RSP20190993 A RS P20190993A RS 59139 B1 RS59139 B1 RS 59139B1
Authority
RS
Serbia
Prior art keywords
cancer
pyrazol
tautomer
stereoisomer
solvate
Prior art date
Application number
RS20190993A
Other languages
English (en)
Serbian (sr)
Inventor
Thomas Fuchss
Kai Schiemann
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of RS59139B1 publication Critical patent/RS59139B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20190993A 2015-04-02 2016-03-31 Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze RS59139B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15000968 2015-04-02
EP16717560.3A EP3277681B1 (de) 2015-04-02 2016-03-31 Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren
PCT/EP2016/000542 WO2016155884A1 (de) 2015-04-02 2016-03-31 Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren

Publications (1)

Publication Number Publication Date
RS59139B1 true RS59139B1 (sr) 2019-09-30

Family

ID=52814780

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20190993A RS59139B1 (sr) 2015-04-02 2016-03-31 Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze
RS20210817A RS62082B1 (sr) 2015-04-02 2016-03-31 Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20210817A RS62082B1 (sr) 2015-04-02 2016-03-31 Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze

Country Status (24)

Country Link
US (5) US10457677B2 (enExample)
EP (3) EP3277681B1 (enExample)
JP (2) JP6791873B2 (enExample)
KR (2) KR20240044525A (enExample)
CN (3) CN111689963A (enExample)
AU (4) AU2016239270B2 (enExample)
BR (1) BR122019005502B1 (enExample)
CA (1) CA2981365A1 (enExample)
DK (2) DK3277681T3 (enExample)
ES (3) ES2741853T3 (enExample)
HR (2) HRP20191396T1 (enExample)
HU (2) HUE054745T2 (enExample)
IL (3) IL254714B (enExample)
LT (2) LT3277681T (enExample)
MX (2) MX390537B (enExample)
PL (2) PL3560924T3 (enExample)
PT (2) PT3277681T (enExample)
RS (2) RS59139B1 (enExample)
RU (1) RU2743343C2 (enExample)
SG (2) SG10202002181UA (enExample)
SI (2) SI3277681T1 (enExample)
TR (1) TR201911244T4 (enExample)
WO (1) WO2016155884A1 (enExample)
ZA (1) ZA201707423B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE054745T2 (hu) * 2015-04-02 2021-09-28 Merck Patent Gmbh Imidazolonilkinolinok és alkalmazásuk ATM-kináz-inhibitorokként
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
WO2018153365A1 (zh) * 2017-02-27 2018-08-30 上海瑛派药业有限公司 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
JP2021510701A (ja) 2018-01-12 2021-04-30 プロリンクス エルエルシー 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤
CA3093499A1 (en) 2018-03-14 2019-09-19 Merck Patent Gmbh Compounds and uses thereof to treat tumors in a subject
BR112020018006A2 (pt) 2018-04-12 2021-01-12 Bayer Aktiengesellschaft Derivados de n-(ciclopropilmetil)-5-(metilsulfonil)-n-{1-[1-(pirimidin-2-il)-1h-1,2,4-triazol-5-il]etil}benzamida e os derivados correspondentes de piridina-carboxamida como pesticidas
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN110386932A (zh) 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
GB201814487D0 (en) * 2018-09-06 2018-10-24 Cycle Pharmaceuticals Ltd Cancer
CN109045042A (zh) * 2018-09-21 2018-12-21 上海交通大学医学院附属上海儿童医学中心 Atm抑制剂在制备抑制急性淋巴细胞性白血病复发的药物中的应用
CN112771045B (zh) * 2018-09-30 2022-04-19 南京明德新药研发有限公司 喹啉并吡咯烷-2-酮类衍生物及其应用
RS65518B1 (sr) 2019-03-27 2024-06-28 Merck Patent Gmbh Jedinjenja imidazolonilhinolina i njihova terapijska upotreba
CN119684291A (zh) * 2019-07-30 2025-03-25 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
IL292613A (en) * 2019-11-01 2022-07-01 Ares Trading Sa Combined inhibition of pd-1, tgfβ and atm together with radiotherapy for the treatment of cancer
US11685734B2 (en) 2019-12-04 2023-06-27 Chdi Foundation, Inc. ATM kinase inhibitors and compositions and methods of use thereof
CN115003672A (zh) * 2020-01-09 2022-09-02 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
CN115380031A (zh) * 2020-03-30 2022-11-22 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
EP4168010A1 (en) * 2020-06-18 2023-04-26 Merck Patent GmbH Compounds for the treatment of viral infections
US20230256110A1 (en) 2020-06-24 2023-08-17 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atm inhibitor
MX2023002792A (es) 2020-09-18 2023-03-16 Merck Patent Gmbh Preparacion farmaceutica.
WO2022060377A1 (en) * 2020-09-21 2022-03-24 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
CN115232122B (zh) * 2021-04-23 2024-05-31 石药集团中奇制药技术（石家庄）有限公司 炔类化合物及其制备和应用
CN115716829B (zh) * 2022-11-13 2024-05-31 药康众拓(江苏)医药科技有限公司 一种喹啉并咪唑酮联氘代吡唑类化合物及其应用
US12384808B2 (en) 2022-11-23 2025-08-12 Forward Therapeutics, Inc. Modulators of TNF-α activity
WO2025157979A1 (en) 2024-01-26 2025-07-31 Merck Patent Gmbh Synthesis route for preparing 8-(1,3-dimethyl-1h-pyrazol-4-yl)-1-(sa)-(3-fluoro-5-methoxy-pyridin-4-yl)-7-methoxy-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
DE60001623T2 (de) * 1999-12-03 2003-12-18 Pfizer Products Inc., Groton Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
WO2006100226A1 (en) * 2005-03-21 2006-09-28 Ferrer Internacional, S. A. Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
BRPI0617987A2 (pt) * 2005-10-06 2011-08-16 Auspex Pharmaceuticals Inc composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
KR101472607B1 (ko) 2007-02-20 2014-12-15 노파르티스 아게 지질 키나제 및 ｍＴＯＲ의 이중 억제제로서의 이미다조퀴놀린
CA2717948C (en) 2008-03-26 2016-09-06 Novartis Ag 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
RS54560B1 (sr) 2008-06-10 2016-06-30 Abbvie Inc. Triciklična jedinjenja
RU2519200C2 (ru) 2008-10-01 2014-06-10 Новартис Аг Применение антагонистов smoothened для лечения связанных с путем hedgehog нарушений
AU2010255727B2 (en) 2009-06-04 2013-02-28 Novartis Ag 1H-imidazo[4,5-c]quinolinone derivatives
JP2012528829A (ja) 2009-06-04 2012-11-15 ノバルティス アーゲー １Ｈ−イミダゾ［４，５−ｃ］キノリノン化合物
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN102803227B (zh) * 2010-03-16 2016-01-20 默克专利有限公司 吗啉基喹唑啉
US8791113B2 (en) * 2010-06-28 2014-07-29 Merck Patent Gmbh 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
CN102372711B (zh) 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
US20130245061A1 (en) 2010-12-03 2013-09-19 Novartis Ag Pharmaceutical compositions
CN103012398B (zh) 2011-09-19 2015-10-14 上海恒瑞医药有限公司 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
WO2013154778A1 (en) 2012-04-11 2013-10-17 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
WO2013184621A1 (en) 2012-06-06 2013-12-12 Novartis Ag Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
NO2714752T3 (enExample) 2014-05-08 2018-04-21
HUE054745T2 (hu) 2015-04-02 2021-09-28 Merck Patent Gmbh Imidazolonilkinolinok és alkalmazásuk ATM-kináz-inhibitorokként

Also Published As

Publication number Publication date
KR102652052B1 (ko) 2024-03-27
US20200325137A1 (en) 2020-10-15
ES2946507T3 (es) 2023-07-20
EP3868761B1 (de) 2023-03-01
CN111689963A (zh) 2020-09-22
KR20170132323A (ko) 2017-12-01
AU2022256215A1 (en) 2022-11-24
US20190211013A1 (en) 2019-07-11
LT3560924T (lt) 2021-08-25
HUE045477T2 (hu) 2019-12-30
CN107889488B (zh) 2020-08-11
EP3868761A1 (de) 2021-08-25
RS62082B1 (sr) 2021-08-31
CA2981365A1 (en) 2016-10-06
AU2020204241A1 (en) 2020-07-16
EP3560924B1 (de) 2021-03-31
PT3277681T (pt) 2019-08-20
MX390537B (es) 2025-03-20
PL3277681T3 (pl) 2019-10-31
SG10202002181UA (en) 2020-05-28
AU2020204241B2 (en) 2022-11-17
IL271494A (en) 2020-02-27
DK3277681T3 (da) 2019-07-29
IL254714A0 (en) 2017-11-30
SI3560924T1 (sl) 2021-08-31
IL282584B (en) 2021-12-01
IL254714B (en) 2020-01-30
EP3560924A1 (de) 2019-10-30
SI3277681T1 (sl) 2019-09-30
JP7111790B2 (ja) 2022-08-02
US11608338B2 (en) 2023-03-21
AU2016239270A1 (en) 2017-11-16
PT3560924T (pt) 2021-07-02
US10975075B2 (en) 2021-04-13
CN107889488A (zh) 2018-04-06
BR122019005502B1 (pt) 2024-02-27
HRP20210981T1 (hr) 2021-09-17
AU2025200385A1 (en) 2025-02-13
BR112017020941A2 (pt) 2018-07-10
RU2017138100A (ru) 2019-05-08
WO2016155884A1 (de) 2016-10-06
RU2743343C2 (ru) 2021-02-17
CN111747952A (zh) 2020-10-09
SG11201708065QA (en) 2017-10-30
IL282584A (en) 2021-06-30
US20180072715A1 (en) 2018-03-15
ES2741853T3 (es) 2020-02-12
JP6791873B2 (ja) 2020-11-25
MX2017012613A (es) 2018-01-24
US10745399B2 (en) 2020-08-18
KR20240044525A (ko) 2024-04-04
US20230203034A1 (en) 2023-06-29
LT3277681T (lt) 2019-08-12
DK3560924T3 (da) 2021-06-28
JP2018510191A (ja) 2018-04-12
TR201911244T4 (tr) 2019-08-21
HUE054745T2 (hu) 2021-09-28
JP2021046403A (ja) 2021-03-25
RU2017138100A3 (enExample) 2019-10-04
NZ774407A (en) 2024-09-27
MX376947B (es) 2025-03-07
EP3277681A1 (de) 2018-02-07
IL271494B (en) 2021-05-31
US10457677B2 (en) 2019-10-29
NZ736641A (en) 2024-09-27
AU2016239270B2 (en) 2020-03-26
PL3560924T3 (pl) 2021-10-11
EP3277681B1 (de) 2019-05-08
HRP20191396T1 (hr) 2019-11-01
US20210198257A1 (en) 2021-07-01
MX2020011558A (es) 2022-03-09
ES2880626T3 (es) 2021-11-25
ZA201707423B (en) 2021-05-26

Similar Documents

Publication Publication Date Title
RS59139B1 (sr) Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze
US20250188080A1 (en) Imidazolonylquinoline compounds and therapeutic uses thereof
RS57838B1 (sr) Arilhinazolini
KR20230104754A (ko) 동종항체 유도 만성 이식편대숙주병의 치료 및 예방방법
WO2019057757A1 (en) 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
RU2822479C2 (ru) Соединения имидазолонилхинолина и их терапевтическое применение
HK40068646B (en) Imidazolonylquinoline compounds and therapeutic uses thereof
HK40068646A (en) Imidazolonylquinoline compounds and therapeutic uses thereof
BR112017020941B1 (pt) Imidazolonilquinolinas, seus usos, composições farmacêuticas, e kit